ANGPLT3 interfering RNA therapy reduces triglyceride levels in mixed hyperlipidemia
1. Zodasiran, an RNA interference (RNAi) therapy targeting angiopoietin-like 3 (ANGPTL3), resulted in a dose-dependent reduction in ANGPTL3 and triglyceride ...
Tag: mixed hyperlipidemia
Plozasiran reduces triglyceride levels in mixed hyperlipidemia
1. In this randomized controlled trial, among patients with mixed hyperlipidemia, plozasiran significantly reduced fasting triglyceride levels compared with placebo. ...
Zodasiran associated with reduced triglyceride levels among adults with mixed hyperlipidemia
1. In this randomized controlled trial, adults with mixed hyperlipidemia who received zodasiran had dose-dependent decreases in triglyceride levels compared ...